Journal Pre-proof Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma: A Single Institution Experience Dilan A. Patel, MD, Tanner M. Johanns, MD PhD, Kathryn Trinkaus, PhD, Nancy L. Bartlett, MD, Nina Wagner-Johnston, MD, Amanda F. Cashen, MD PII: S2152-2650(19)31991-3 DOI: https://doi.org/10.1016/j.clml.2019.09.604 Reference: CLML 1421 To appear in: Clinical Lymphoma, Myeloma and Leukemia Received Date: 21 June 2019 Revised Date: 9 August 2019 Accepted Date: 21 September 2019 Please cite this article as: Patel DA, Johanns TM, Trinkaus K, Bartlett NL, Wagner-Johnston N, Cashen AF, Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B- Cell Lymphoma: A Single Institution Experience, Clinical Lymphoma, Myeloma and Leukemia (2019), doi: https://doi.org/10.1016/j.clml.2019.09.604. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2019 Elsevier Inc. All rights reserved.